Norman C. Selby has spent 35 years in the healthcare world in a variety of consulting, managerial, investor and Board roles. His primary activities today are centered on two companies he helped found: Paige.AI, the leading artificial intelligence company in pathology, which he serves as Chairman, and Real Endpoints llc, an information and analytics company focused on the changing pharmaceutical reimbursement and market access landscape, for which he is Vice Chairman. He is also Lead Director of Infinity Pharmaceuticals (INFI), a public biotech company focused in oncology, and on the Boards of Escalier and Oppilan Pharmaceuticals.

Among earlier roles, Mr. Selby has served as the CEO of TransForm Pharmaceuticals, Executive Chairman of Windhover Information, Founder and Executive Chairman of Physicians Interactive Holdings, and Board member of Millennium Pharmaceuticals (MLNM).

Mr. Selby spent the bulk of his career at McKinsey & Company where he was Director (Senior Partner) in the firm’s New York office, and head of the firm’s Global Pharmaceuticals and Medical Products Practice. From 1987-1989, Mr. Selby took a leave of absence from McKinsey to serve as Chief Operating Officer of the New York Blood Center, the largest community blood organization in the country, where he led its financial and operational turnaround.

Mr. Selby serves on the Board of Trustees of the Central Park Conservancy and the Memorial Sloan-Kettering Cancer Center, and is a member of the Council on Foreign Relations, all based in New York City. He is also on the Advisory Board of the Harvard Business School’s Healthcare Initiative.

Mr. Selby holds a B.A. in Architecture from Yale College and an M.B.A. with Distinction from the Harvard Graduate School of Business Administration.